中國同輻(01763.HK)成功簽約尼日利亞核醫療設備整體供應項目
格隆匯7月8日丨中國同輻(01763.HK)公吿,近日,中國同輻成功簽約尼日利亞核醫療設備整體供應項目。
本項目為尼日利亞新建癌症腫瘤診療中心項目,中國同輻作為國內核技術應用的領軍企業,積極響應國際原子能機構(IAEA)“希望之光”倡議,根據客户需求組織中國方案,積極為非洲客户建立、加強核醫學診療能力。同時,中國同輻積極響應公司控股股東中國寶原投資有限公司及中國核工業集團有限公司“整體•協同”倡議,推動中國核動力研究設計院設備製造廠後裝機獲得業主認可。在中國同輻內部積極組織協同,以中國同輻附屬公司成都中核高通同位素股份有限公司放射源為後裝機配備中國芯。此外,本項目還包括醫用迴旋加速器、CT模擬機等設備。最後在中核集團非洲區域代表處的大力支持下,中國同輻成功斬獲該項目。
本項目的落地是中國同輻整體推動核技術應用產品及產業走出去在非洲地區邁出的重要一步,是中國同輻首次成功落地核醫療裝備整體供應項目,將有效推動中國同輻核技術應用產業在非洲逐步走深走實,進一步為中國同輻國際化經營水平提升貢獻力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.